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tinguished by chronic transmural inflammation and
destruction of the elastic media.1 Although these
processes are considered critical in the pathophysiology of
aneurysmal degeneration, the exact causes of aneurysm
growth and rupture are still unknown. Therefore, better
understanding of molecular mechanisms is an important
step toward the development of new therapeutic strategies
for AAAs.
Increased expression of several genes relevant to the
pathophysiology of AAAs is well documented, particularly
enzymes of the matrix metalloproteinase (MMP) family
and their endogenous inhibitors.2,3 Evidence indicates
that other enzymes may be important in AAAs, including
plasminogen activators, serine elastases, and cysteine pro-
tease; genes encoding proinflammatory cytokines, chemo-
tactic mediators, and cell adhesion molecules have also
been implicated in aneurysmal degeneration. Despite the
many pathophysiologic insights obtained in the past
Degenerative abdominal aortic aneurysms (AAAs) are
associated with aging, atherosclerosis, and an undefined
familial tendency, and the histopathology of AAAs is dis-
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BASIC RESEARCH STUDIES
Simultaneous analysis of 1176 gene products 
in normal human aorta and abdominal aortic
aneurysms using a membrane-based
complementary DNA expression array
William S. Tung, MD,a Jason K. Lee, MD,a and Robert W. Thompson, MD,a,b,c St Louis, Mo
Background: A number of changes in gene expression have been described in abdominal aortic aneurysms (AAAs), but
the spectrum of molecular alterations in this disease is unknown. The purpose of this study was to characterize the
expression of approximately 1000 gene products in human AAA tissue and to compare the profile of genes expressed
in AAAs with that observed in normal aorta.
Materials and Methods: Total RNA was isolated from abdominal aortic wall tissues (4 AAAs and 4 normal aortas), and
array-specific [32P]–labeled complementary DNA (cDNA) probes were created with reverse transcription. The cDNA
probes were hybridized with nylon membranes containing an array of 1176 cDNA clones (AtlasArray Human 1.2 I;
Clontech, Palo Alto, Calif), and autoradiographs were scanned to identify the patterns of gene expression characteris-
tic of each tissue type. Densitometric analysis was used to standardize the expression of individual genes to a panel of
housekeeping controls, and differential gene expression was defined by a signal ratio of at least 2:1. 
Results: One hundred forty-five (12.3%) of the 1176 genes were consistently expressed in aortic tissue. Thymosin β-4
was the most abundant of 101 transcripts detected in both AAAs and normal aorta, whereas 44 genes exhibited dif-
ferential patterns of expression (39 predominant in AAAs and 5 in normal aorta). Densitometric analysis confirmed
differences in expression for 20 of these gene products between AAAs and normal aorta, with the greatest increases
seen for myeloid cell nuclear differentiation antigen (31-fold), cathepsin H (30-fold), platelet-derived growth factor–A
(23-fold), apolipoprotein E (13-fold), gelatinase B/matrix metalloproteinase-9 (12-fold), and interleukin-8 (11-fold).
The only gene products substantially decreased in AAAs were myosin light chain kinase (39-fold) and β-1 integrin
(twofold). AAA tissues thereby exhibited a distinct pattern of gene expression reflecting chronic inflammation, extra-
cellular matrix degradation, atherosclerosis, and smooth muscle cell depletion. 
Conclusions: cDNA expression arrays provide a powerful new approach to help identify the molecular mechanisms respon-
sible for aneurysmal degeneration. Further studies will be needed to elucidate the functional and pathophysiologic sig-
nificance of the individual genes that exhibit altered levels of expression in AAA tissue. (J Vasc Surg 2001;34:143-50.)
decade, the spectrum of gene products altered in AAAs
remains unknown. 
Traditional approaches to elucidate broad alterations
in gene expression include subtractive complementary
DNA (cDNA) hybridization and messenger RNA
(mRNA) differential display. Each of these techniques can
be used to effectively detect mRNA transcripts expressed
in a given tissue over a comparable control, but they often
reveal numerous (unidentified) gene products that must
be further characterized by independent and laborious
methods. In recent years, the development of microchip-
or membrane-based cDNA arrays has made it possible to
examine the simultaneous expression of multiple gene
products of known identity in the same experiment.4-7
These methods greatly facilitate the identification of
altered patterns of gene expression in a given tissue,
including detection of unanticipated changes. In addition
to the sensitivity and specificity now achievable with
microarray techniques, advances in analytical software
have permitted the rapid analysis of cDNA expression in a
semiquantitative fashion.8 Because this approach has the
potential to reveal novel pathophysiologic insights, the
purpose of this study was to characterize the simultaneous
expression of approximately 1000 gene products in
human AAA tissue and to compare the expression profile
of AAAs with that of normal aorta.
MATERIALS AND METHODS
Aortic tissues. Full-thickness aortic wall specimens
were obtained from four patients undergoing elective sur-
gical repair for infrarenal AAAs (2 men [aged 84 and 80
years] and 2 women [aged 76 and 57 years]; mean age,
74.3 ± 6.0 years). The mean aneurysm size was 5.7 ± 0.3
cm as measured with computed tomography (5.5 and 5.1
cm [male patients] 6.3 and 6.0 cm [female patients]), and
all patients were symptom free before repair. For compar-
ison, normal infrarenal aortic wall without visible evidence
of atherosclerosis was obtained from four transplant
donors at the time of organ harvest (3 men [aged 43, 18,
and 14 years] and 1 woman [aged 36 years]; mean age
27.8 ± 7.0 years). Tissue specimens were snap-frozen in
liquid nitrogen immediately on procurement and were
stored at –70°C before nucleic acid extraction. All tissues
were obtained with approval by the Washington
University School of Medicine Human Research Subjects
Committee.
Isolation of RNA and preparation of labeled cDNA
probes. Aortic tissue samples were pulverized under liquid
nitrogen, and total RNA was isolated with Trizol reagent
(Gibco BRL, Grand Island, NY), as described.9 Each RNA
sample was further extracted to eliminate excess protein
and treated with RQ1 ribonuclease–free deoxyribonuclease
(Promega, Madison, Wis) to eliminate residual DNA con-
tamination. Labeled cDNA probes were prepared with
reagents and protocols provided with the AtlasArray
Human 1.2 I cDNA Expression Array kit from Clontech
Laboratories, Inc (Palo Alto, Calif). For each specimen, 
5 µg of total RNA was incubated with a mixture of array-
specific oligonucleotide primers and 200 units of Moloney
murine leukemia virus (MMLV) reverse transcriptase
(Clontech) in the presence of [α-32P]dATP (Amersham
Pharmacia Biotech, Piscataway, NJ). In some cases, reverse
transcription was performed with 400 units of Superscript
II (Gibco BRL), a ribonuclease H MMLV mutant that
appeared to produce equal or superior labeling. The
labeled cDNA probes were purified with column chro-
matography to remove unincorporated isotope before use
(Chromospin-20; Clontech).
Membrane hybridization. Each labeled cDNA probe
was mixed into hybridization buffer (ExpressHyb;
Clontech), then incubated overnight (68°C) with a nylon
membrane containing bound cDNA clones corresponding
to 1176 different human genes (AtlasArray Human 1.2 I;
Clontech). After hybridization, membranes were washed
under stringent conditions and exposed to radiographic
film (Kodak Biomax MS, Rochester, NY). Membranes
were stripped before reuse according to the manufac-
turer’s instructions.
Analysis of data. Autoradiographs were scanned and
analyzed with AtlasImage software (Clontech). This pro-
gram allows assignment of numerical values to each point
on the array in accord with the intensity of the hybridiza-
tion signal on the blot and the adjacent background den-
sity. For differential gene expression between aneurysmal
and normal aortic tissues to be determined, the signals on
each array were standardized with a series of housekeeping
genes present on the same membrane (ubiquitin, glycer-
aldehyde phosphate dehydrogenase, and the 60S riboso-
mal protein L13A), and numerical data from each array
were used to generate a computationally derived consen-
sus array for each tissue type. For each gene represented
on the two consensus arrays, the ratio of gene expression
levels was determined by dividing the signal intensity on
the AAA array by that on the normal aorta array.
Differential gene expression was considered significant
when the signal ratio was greater than 2:1.
RESULTS
Fig 1 shows representative autoradiographs of the
AtlasArray Human 1.2 I membrane after hybridization with
cDNA probes derived from AAA tissue and normal aorta.
By initial inspection, aortic tissue samples exhibited a cDNA
expression profile consisting of up to 221 of 1176 genes
represented on the array. Because only 145 of these genes
were consistently expressed in either AAAs or normal aorta
(ie, detected in at least half of the specimens examined), the
remaining analysis was confined to these transcripts (12.3%
of the total number of genes analyzed). 
Consistency of gene expression. Twenty-one
(14.5%) of the 145 genes were strongly expressed in both
AAAs and normal aorta, and 80 (55.2%) were detected at
lower levels in both tissue types (see the online-only sup-
plement to this report for a complete list). The most abun-
dant transcript expressed in all samples was thymosin β-4,
a cytoplasmic protein that regulates actin fibril assembly
during cell migration and chemotaxis.10 Additional genes
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expressed at high levels in both tissue types included pro-
teins involved in RNA transcription, proto-oncogenes
involved in cell signaling and transcription, and other thy-
mosin family proteins. Genes encoding heat shock pro-
teins (HSP86 and HSP27) and proteins involved in
inflammation and cell growth were also expressed at high
levels in both AAAs and normal aorta, as were calgranulin
A and tissue inhibitor of metalloproteinases (TIMP)-1.
The consistently high levels of expression for these genes
suggest that they are required to maintain tissue home-
ostasis in the normal and diseased abdominal aorta.
Thirty-nine (26.9%) of the 145 genes were expressed
exclusively or predominantly in AAAs (ie, detectable in 
> 75% of AAA specimens and < 25% of normal aortas).
Genes expressed exclusively in AAA tissue included those
involved in atherosclerosis (apolipoprotein E [apo E] and
the thrombin receptor), inflammatory responses
(myeloid cell nuclear differentiation antigen [MNDA],
C-X-C chemokine receptor type 4, lymphocyte adaptor
protein LNK, heat shock transcription factor–1, inter-
leukin-2 [IL-2] receptor-γ, and macrophage inflamma-
tory protein-2α), intracellular signaling (v-YES-1
sarcoma-related oncogene Lyn, protein kinase C delta,
protein kinase SGK, RAL A GTP-binding protein, and
transducin β-1), and extracellular matrix degradation
(gelatinase B/MMP-9). The prevalence of these gene
products in AAAs supports the recognized role of these
biological processes in aneurysmal degeneration. In con-
trast, only five (3.4%) of the 145 genes were expressed
exclusively in normal aorta (ie, detectable in no AAA
specimens and > 75% of normal aortas). The most strik-
ing of these differences was observed for myosin light
chain kinase, a cytoskeletal protein that regulates con-
traction and migration.11
Fig 2 shows representative autoradiographs of the part
of the AtlasArray Human 1.2 I membrane that corre-
sponds to extracellular matrix proteinases and their
inhibitors (Sector F, Rows m and n). TIMP-1 was promi-
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nently expressed in all normal and aneurysmal tissues,
whereas plasminogen activator inhibitor–1 was expressed
in three of four AAAs and only two of four normal aortas.
Gelatinase B/MMP-9 was substantially and exclusively
increased in aneurysms, but it is notable that other MMPs
and TIMPs known to be produced in AAAs (eg, MMP-2,
MMP-3, MMP-12, MMP-13, and TIMP-2) were gener-
ally expressed below the limits of detection on the
microarray membranes. The expression of the cysteine
protease, cathepsin D, was also consistently observed in
AAAs, as well as in three of four normal aortas.
Computational analysis. Densitometric analysis con-
firmed semiquantitative differences in expression for 20
gene products between AAAs and normal aorta (Table).
The greatest increases were seen for MNDA (31-fold),
cathepsin H (30-fold), platelet-derived growth factor
(PDGF)–A chain (23-fold), apo E (13-fold), gelatinase
B/MMP-9 (12-fold), and IL-8 (11-fold). Additional tran-
scripts significantly increased in AAAs included the C-X-C
chemokine receptor HM89, Fli-1 oncogene, intercellular
adhesion molecule (ICAM)–1 and its receptor (integrin
alpha L; CD11a/-CD18), two immediate-early response
genes (transcription factor ETR 101 and early growth
response–1), the chondroitin/dermatan sulfate proteogly-
can core protein (decorin), and RANTES (Regulated on
Activation Normal T cell Expressed and Secreted). In con-
trast, the only genes substantially decreased in AAAs were
myosin light chain kinase (39-fold) and integrin β-1
(twofold). AAA tissues thereby exhibited a distinct pattern
of gene expression reflecting the association of this disease
with chronic inflammation, extracellular matrix degrada-
tion, atherosclerosis, and smooth muscle cell depletion. 
DISCUSSION
For the initial application of gene expression profiling
to the study of aortic aneurysms, we used a commercially
available membrane array that contains cDNA sequences
from 1176 known human genes (approximately 0.6%-2% of
Fig 1. cDNA membrane arrays for AAAs and normal aorta. Representative autoradiographs are shown for membranes blotted with
radiolabeled cDNA derived from an AAA and a normal aorta. Each blot is superimposed on an orientation grid corresponding to the
AtlasArray Human 1.2 I membrane (Clontech), which contains bound cDNA clones from 1176 distinct gene products. Gene products
represented by each location on grid are identified by accessing the manufacturer’s interactive Web site, http://atlasinfo.clontech.com
(follow link to AtlasInfo 2.0 and select Human 1.2 I).
the human genome). We chose this particular array to
detect genes involved in a wide spectrum of biological
processes, including tumorigenesis, signal transduction, cell
cycle regulation, apoptosis, inflammation and immune
responses, DNA synthesis and repair, and matrix protein
turnover. A number of other membrane- or microchip-
based microarrays might have been selected for this study,
and in the future it will be valuable to use either broader or
more disease-specific arrays to investigate additional alter-
ations that might occur in AAAs. To simplify the scope of
this initial study, we also chose to characterize the gene
expression profile of large asymptomatic AAAs by compar-
ison with normal aorta obtained from young organ trans-
plant donors, rather than specimens obtained from patients
with unstable AAAs or those with aortoiliac occlusive dis-
ease. This represents an important limitation of the study,
in that it precludes drawing conclusions about the alter-
ations in gene expression in AAAs that might otherwise be
attributable to aging or atherosclerosis alone. Nevertheless,
this initial approach provides a sound basis for further inves-
tigation, because the expression profile of normal human
abdominal aorta has not been previously described.
Moreover, it will facilitate interpretation of further studies
designed to specifically compare gene expression profiles in
AAAs with age-matched atherosclerotic tissue and among
AAAs at various stages of disease progression.
The most abundant transcript detected in all aortic tis-
sue specimens was thymosin β-4, a 4-kD protein originally
characterized in the thymus.10 Thymosin β-4 interacts
strongly with G-actin in the cytosol and is thought to play
a role in regulating actin fibril assembly during cellular
migration and chemotaxis.12,13 Recent studies have attrib-
uted a variety of additional functions to thymosin β-4 as
an extracellular mediator, including the induction of
endothelial cell chemotaxis and MMP expression in
vitro.14,15 Moreover, thymosin β-4 sulfoxide is induced in
glucocorticoid-stimulated monocytes and macrophages,
where it acts as an extremely potent anti-inflammatory
agent.16 The marked expression of thymosin β-4 in
human aorta will thereby require further investigation to
determine if this protein might participate in modulating
inflammation in the vascular wall. 
Given the complex nature of the pathologic changes in
AAAs and the large number of genes examined in this
study, we found that AAA tissues were characterized by a
surprisingly limited repertoire of altered gene products;
substantial differences in expression between AAAs and
normal aorta were observed for only 20 transcripts (1.7% of
the genes examined). Previous studies on aortic aneurysms
have revealed increased expression for several of the gene
products detected in the current analysis. For example, we
measured a 12-fold increase in the expression of gelatinase
B/MMP-9 in AAAs versus normal aorta, which is in agree-
ment with the 23-fold increase in MMP-9 mRNA recorded
by Tamarina et al,2 using competitive reverse transcriptase-
polymerase chain reaction, and the 10-fold increase
reported by Elmore et al,3 using Northern analysis.
Although Tamarina et al2 also reported increases in MMP-
1 (12-fold), TIMP-1 (1.7-fold), and TIMP-2 (4.5-fold) in
AAAs, we did not detect significant differences in these
gene products in the current study. In addition, we did not
detect expression of either MMP-12 or MMP-13, two gene
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Fig 2. Expression of matrix proteinases and inhibitors in normal and AAAs. Representative autoradiographs are shown for portion of
the AtlasArray Human 1.2 I membrane (Clontech) that contains bound cDNA clones for genes encoding extracellular matrix proteinases
and their inhibitors (Sector F, Rows m and n), after blotting with radiolabeled cDNA derived from normal aorta (I) and four different
AAA specimens (I-IV). Gene products represented by each location on membrane are identified, along with glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as housekeeping control. PAI, Plasminogen activator inhibitor; TIMP, tissue inhibitor of metalloproteinases;
MMP, matrix metalloproteinase; 
products previously reported to be elevated in human AAA
tissue by other techniques.9,17 The differences in the results
of these studies may be explained by several factors, partic-
ularly the higher threshold for gene expression that appears
to be required for detection in cDNA expression arrays
compared with other techniques. It is therefore likely that
our hybridization assays failed to detect at least some
mRNA species present in low abundance. In addition, we
used relatively strict criteria to define differences in expres-
sion in this study, and comparison of mRNA expression lev-
els between cDNA arrays and other techniques remains
only semiquantitative and indirect. Other important con-
siderations in interpreting our results include the hetero-
geneity in expression of various MMPs (and potentially
other gene products) between different aneurysm tissue
samples and the variable quality of RNA extracted from
degenerative human aortic tissue.9 Therefore, it is necessary
to reemphasize that cDNA expression arrays are most valu-
able in the detection of novel, unanticipated alterations in
gene expression, and that the strength of this method cur-
rently resides in the capacity to characterize patterns of gene
expression rather than to quantify the expression of individ-
ual gene products. The remaining discussion is thereby lim-
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ited to genes exhibiting the most prominent differential
patterns of expression between AAAs and normal aorta, as
organized by biological processes that relate to disease
development or progression. 
Extracellular matrix proteolysis. AAAs are clearly
associated with accelerated degradation of aortic wall
structural proteins, and our findings confirm the impor-
tance of this process in aneurysm disease. For example,
gelatinase B/MMP-9 is an elastolytic proteinase known to
be elevated at both the protein and mRNA levels in
aneurysm tissue, where it is localized to aneurysm-infil-
trating macrophages by immunohistochemistry and in situ
hybridization.18,19 Both pharmacologic inhibition and tar-
geted gene disruption of gelatinase B/MMP-9 have been
shown to specifically inhibit the development of experi-
mental AAAs.20 This study therefore supports the view
that gelatinase B/MMP-9 plays a major role in aneurysmal
degeneration. In accordance with previous studies, we
found that TIMP-1 is also expressed at high levels in AAA
tissues and in normal aorta.2,3,18,19 Although TIMP-1
mRNA appeared to be expressed in AAAs at higher levels
than gelatinase B/MMP-9, it is not possible to extrapolate
this difference to the protein level; it therefore remains
Differentially regulated genes in AAAs versus normal aorta (computational analysis)
Normalized density ratio
Site* Gene product name (GenBank reference)† AAA to normal
Genes significantly upregulated in AAAs (n = 18)
A-1-11 MNDA (M81750) 31 to 1
F-k-8 Cathepsin H (X07549) 30 to 1
F-g-7 PDGF, A Chain (PDGF-A) (X06374) 23 to 1
B-c-4 apo E (M12529) 13 to 1
F-m-7 Gelatinase B; MMP-9 (J05070) 12 to 1
F-g-14 IL-8 (Y00787) 11 to 1
B-d-13 CXC chemokine receptor type 4 (HM89) (D10924) 8 to 1
E-b-7 Fli-1 oncogene (M93255) 7 to 1
E-i-14 Integrin alpha L (CD11a) (Y00796) 5 to 1
E-g-14 ICAM-1 (J03132) 4 to 1
E-b-5 Transcriptional regulator ISGF3, gamma subunit (M87503) 4 to 1
E-3-11 ZFP-36 (tristetraproline) (M92843) 3 to 1
E-a-11 Transcription factor ETR 101 (M62831) 3 to 1
E-g-11 Decorin (M14219) 3 to 1
D-f-9 Acyl-CoA-binding protein (M14200) 3 to 1
F-e-10 RANTES protein T-cell specific (M21121) 2 to 1
E-h-5 Cell adhesion protein SQM1 (M33374) 2 to 1
E-a-10 Transcription factor ETR103 (M62829) 2 to 1
Genes significantly downregulated in AAAs (n = 2)
B-g-12 MLCK (U48959) 1 to 39
E-I-09 Integrin beta-1 (X07979) 1 to 2
Gene products were identified from autoradiographs of AtlasArray Human 1.2 I membranes (Clontech) that were hybridized with labeled cDNA samples
from four AAAs and four normal aortas. For each autoradiograph, the signal intensities for individual gene products were standardized to a panel of four
different housekeeping genes, and consensus array data were composed for each tissue type with analytical software supplied by the manufacturer.
Differential expression of individual gene products was based on a standardized density intensity ratio of at least 2:1 (AAA vs normal aorta). 
*Sites refer to the location of the target cDNA on the AtlasArray Human 1.2 I membrane by Sector Web site, http://atlasinfo.clontech.com (follow the
link to AtlasInfo 2.0 and select Human 1.2 I). Each array location site is hyperlinked to the manufacturer’s proprietary database for additional information
about the gene and its functional properties.
†GenBank reference numbers are hyperlinked to the National Center for Biotechnology Information database maintained by the National Library of
Medicine and National Institutes of Health.
apo E, Apolipoprotein E; ICAM, intercellular adhesion molecule; IL, interleukin; MLCK, myosin light chain kinase; MMP, matrix metalloproteinase;
MNDA, myeloid cell nuclear differentiation antigen; PDGF, platelet-derived growth factor; ZFP, zinc finger protein.
unclear if the TIMP-1 produced in AAAs is sufficient to
inhibit the activity of gelatinase B/MMP-9 or other
MMPs in vivo. Finally, it is notable that two cysteine pro-
teases (cathepsins D and H) were also prominently
expressed in AAAs. Others have described increased levels
of cathepsins in atherosclerosis and aneurysm tissue,21,22
whereas low levels of cystatin C, the principle cathepsin
inhibitor, appear to be associated with subclinical aortic
dilatation.23 Because cathepsin H has not been previously
linked to aneurysm disease, the significantly elevated
expression of this gene suggests that it may be a fruitful
target for further investigation.
Inflammation. Not surprisingly, several genes associ-
ated with chronic inflammation were found to be upregu-
lated in AAA tissue. MNDA is a nuclear protein expressed
specifically in human myelomonocytic cell types, including
monocytes/macrophages and granulocytes.24-26 Because
this protein is involved in regulating gene expression
uniquely associated with the differentiation process or
function of mononuclear phagocytes, it appears likely that
MNDA expression is a reflection of the dense infiltration
of aneurysm tissue by mononuclear phagocytes and their
differentiation to activated tissue macrophages. IL-8 is a
C-X-C chemokine produced by various types of cells on
stimulation with inflammatory stimuli.27 It exerts a variety
of effects on leukocytes, particularly neutrophils,28 and
plays a critical role in the mobilization of hematopoietic
stem cells through its induction of gelatinase B/MMP-
9.29 IL-8 is localized to macrophages and endothelium in
human AAA tissue by immunohistochemistry, and it has
been suggested to play a role in the medial neovascular-
ization that accompanies aneurysmal degeneration.30,31
RANTES is a C-C chemokine expressed predominantly in
T lymphocytes, and it plays a role in monocyte recruit-
ment and other aspects of chronic inflammation.32,33
Because increased production of RANTES has not been
previously associated with aneurysm disease, the regula-
tion and function of this protein will be of interest in
future studies. Finally, transcripts encoding several addi-
tional proteins involved in leukocyte trafficking and cell
adhesion were elevated in AAAs, including the
immunoglobulin-like glycoprotein, ICAM-1 (CD54), and
CD11a/CD18 (LFA-1), one of two leukocyte surface β2
integrins that binds ICAM-1.34,35 ICAM-1 is prominently
expressed by endothelial cells and macrophages in coro-
nary, carotid, and aortic atherosclerotic plaques, where it
is associated with neovascularization and chronic inflam-
mation.36-38 It has also been demonstrated in the outer
aortic wall of AAAs, and its soluble form is secreted by
AAA explants in vitro.38,39 The adhesive interactions
mediated by these proteins are thought to be important
for transendothelial migration of leukocytes to sites of
inflammation and costimulation of T cell activation, and
their functional importance in vascular pathology has been
recently demonstrated in ICAM-1 knockout mice.40,41
Atherosclerosis. Although the precise relationship
between atherosclerosis and aneurysmal degeneration
remains unclear, their frequent association and shared risk
factors suggest common pathophysiologic mechanisms. This
assertion is supported by the observation that AAAs exhib-
ited increased expression of several gene products thought
to be important in atherosclerosis, including PDGF, throm-
bin receptor, and apo E. Both PDGF and thrombin are
potent smooth muscle cell mitogens thought to participate
in the proliferative events responsible for atheroma forma-
tion,42,43 whereas apo E, through its profound effects on
cholesterol and lipid homeostasis, is thought to be protec-
tive against atherosclerosis.44 Indeed, targeted deletion of
the apo E gene in mice forms the basis of an important ani-
mal model for complex atherogenesis, and in some cases,
aneurysm formation.45 The potential role of apo E in
human aneurysm disease has not been specifically investi-
gated, and it remains unclear if its upregulated expression in
AAAs is simply a consequence of the atherosclerosis present
in these tissues or if it indicates a more direct relationship to
aneurysmal degeneration. Further gene profiling studies
comparing AAA tissue with age-matched atherosclerotic
control tissues will be valuable in addressing these questions.
Smooth muscle cell depletion. We found that differ-
ential gene expression generally favored an upregulation
of various genes in AAAs as compared with normal aorta.
Although this may be due to the activity of biological
processes involved in aneurysm disease (ie, chemotaxis,
cell proliferation, inflammation, and extracellular matrix
degradation), two gene products found abundantly in
normal aorta, myosin light chain kinase and integrin β-1,
were expressed at significantly decreased levels in AAAs.
Because these proteins regulate contractile and migratory
activity of vascular smooth muscle cells, their decreased
expression likely reflects the pronounced depletion of
medial smooth muscle cells that has been previously
described in human aneurysm tissues.46
In summary, we have used a membrane-based cDNA
microarray to characterize the expression of more than
1000 known human genes in AAA tissue. Our findings
demonstrate that AAAs exhibit a distinct and relatively
limited pattern of differential gene expression compared
with normal aorta, reflecting the association of this disease
with chronic inflammation, extracellular matrix degrada-
tion, atherosclerosis, and smooth muscle cell depletion.
Although the functional significance of the individual gene
products altered in aneurysm tissue will require further
investigation, this study demonstrates the potential of
cDNA expression arrays to help elucidate the molecular
mechanisms responsible for aneurysmal degeneration. 
We thank Dr J. Perren Cobb (Cellular Injury and
Adaptation Laboratory, Section of Burns, Trauma and
Critical Care, Department of Surgery, Washington
University) for valuable discussions.
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